08:00 , Dec 9, 2002 |  BioCentury  |  Finance

Ebb & Flow

The preferred currency for biotech M&A has been stock rather than cash, because most CEOs want to keep the latter to fund R&D. Thus, it's notable that Triangle (VIRS) is the third Warburg Pincus portfolio...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Clinical News

Gencap microparticle DNA delivery technology regulatory update

The Center for Applied Microbiology & Research (Salisbury, U.K.) received U.S. Patent No. 6,309,569 covering methods of encapsulating DNA in microparticles. Zycos, which is the exclusive licensee, said the patent is related to its Gencap...
07:00 , Oct 10, 2001 |  BC Extra  |  Politics & Policy

U.S., U.K. sign bio-terrorism accord

The U.S. and the U.K. on Wednesday signed an agreement to bolster their bio-terrorism defense capabilities. Under the agreement, signed by HHS Secretary Tommy Thompson and UK Minister of Health Alan Milburn, the two countries...
07:00 , Aug 6, 2001 |  BC Week In Review  |  Company News

Genencor, Centre for Applied Microbiology & Research deal

The parties signed an exclusive two-year deal to develop a technology to eliminate prions, believed to be the infectious agent in Bovine Spongiform Encephalopathy (BSE). The deal combines GCOR's protease platform targeting technology, assay development...
08:00 , Jan 2, 2001 |  BC Week In Review  |  Clinical News

Lactic acid producing bacteria data

Ganeden said that its lactic acid producing bacteria significantly reduced density and duration of multiple strains of VRE in mice compared with controls. The results will be published in the Journal of Applied Microbiology. Ganeden...
07:00 , May 22, 2000 |  BC Week In Review  |  Company News

Allergan, The Centre for Applied Microbiology & Research deal

AGN received an exclusive license to commercialize CAMR technology that is based on modifying neurotoxins produced by Clostridium botulinum to treat acute and chronic pain. CAMR will receive up to £20 million ($30.3 million) in...
07:00 , May 15, 2000 |  BC Extra  |  Company News

Allergan licenses neurotoxin technology

AGN received an exclusive license to develop and commercialize neurotoxin-based technology from The Centre for Applied Microbiology & Research (CAMR, Salisbury, U.K.), to treat acute and chronic pain. CAMR could receive up to 20 million...
07:00 , May 15, 2000 |  BC Week In Review  |  Company News

Zycos, Centre for Applied Microbiology & Research deal

Zycos received exclusive worldwide rights to CAMR's patents to develop polymer-based drug delivery systems, excluding defense vaccine products. CAMR is eligible for royalties. Zycos is developing therapeutic vaccines that use biodegradable polymers to deliver DNA...
07:00 , May 9, 2000 |  BC Extra  |  Company News

Zycos gets drug delivery technology

Zycos ( Cambridge , Mass.) acquired an exclusive global license from the Centre for Applied Microbiology & Research to a patent portfolio covering microsphere drug delivery technology, principally for gene delivery. Zycos will pay CAMR...
07:00 , May 8, 2000 |  BC Week In Review  |  Company News

Oxford BioMedica, Centre for Applied Microbiology and Research deal

OXB acquired exclusive global rights to a series of genes isolated by CAMR that encode nitroreductase enzymes. OXB will combine the enzymes with its gene delivery methods to produce a prodrug activation system that targets...